L7R Stock Overview
A pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lipidor AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.066 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.62 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.63% |
| 33 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| L7R | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -94.7% | -1.2% | -0.02% |
| 1Y | -99.6% | -20.1% | 8.2% |
Return vs Industry: L7R underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: L7R underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| L7R volatility | |
|---|---|
| L7R Average Weekly Movement | 1,835.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L7R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L7R's weekly volatility has increased from 1557% to 1835% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Ola Holmlund | lipidor.se |
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
Lipidor AB (publ) Fundamentals Summary
| L7R fundamental statistics | |
|---|---|
| Market cap | €8.28m |
| Earnings (TTM) | -€1.18m |
| Revenue (TTM) | €8.09k |
1,023x
P/S Ratio-7.0x
P/E RatioIs L7R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L7R income statement (TTM) | |
|---|---|
| Revenue | SEK 93.00k |
| Cost of Revenue | SEK 9.26m |
| Gross Profit | -SEK 9.17m |
| Other Expenses | SEK 4.36m |
| Earnings | -SEK 13.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -9,861.29% |
| Net Profit Margin | -14,546.24% |
| Debt/Equity Ratio | 0% |
How did L7R perform over the long term?
See historical performance and comparison